SCHEMBL13639185

SCHEMBL13639185

CC[C@H](NS(=O)(=O)c1ccc(OC)cc1)C(=O)OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 9/20 0.57
MMP13 P45452 7/20 0.57
MMP1 P03956 6/20 0.57
MMP9 P14780 5/20 0.57
MMP8 P22894 3/20 0.57
CA1 P00915 2/20 0.57
CA2 P00918 2/20 0.57
CA12 O43570 2/20 0.55
CA9 Q16790 2/20 0.55
CA14 Q9ULX7 2/20 0.55
ALDH1A1 P00352 2/20 0.55
SLC1A3 P43003 1/20 0.53
SLC1A2 P43004 1/20 0.53
SLC1A1 P43005 1/20 0.53
HSD17B10 Q99714 2/20 0.53
MMP3 P08254 5/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
MMP7 P09237 1/20 0.52
HPGD P15428 1/20 0.52
LMNA P02545 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13643222 1.00 MMP2 (0.57) MMP2MMP13MMP1MMP9MMP8
SCHEMBL13570499 0.88 MMP2 (0.62) MMP2MMP13MMP1MMP9MMP8
SCHEMBL5639380 0.88 MMP2 (0.57) MMP2MMP13MMP1MMP9MMP8
SCHEMBL11887788 0.88 MMP2 (0.62) MMP2MMP13MMP1MMP9MMP8
SCHEMBL13570807 0.88 MMP2 (0.62) MMP2MMP13MMP1MMP9MMP8
SCHEMBL16330779 0.88 HSD17B10 (0.57) MMP2MMP13MMP1MMP9MMP8
SCHEMBL13639192 0.88 MMP2 (0.50) MMP2MMP13MMP1MMP9MMP8
SCHEMBL16330776 0.88 HSD17B10 (0.57) MMP2MMP13MMP1MMP9MMP8
SCHEMBL13639249 0.88 MMP2 (0.50) MMP2MMP13MMP1MMP9MMP8
SCHEMBL7444497 0.87 SLC1A3 (0.56) MMP2MMP13MMP1MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120282180-A1 Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof SIEMENS MEDICAL SOLUTIONS USA, INC. 2012-11-08 US disclosed
EP-2520573-A1 Compounds with matrix-metalloproteinase inhibitory activity Westfälische Wilhelms-Universität Münster (DE) 2012-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120282180-A1 Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof MMP1, MMP17, MMP25 MMP2 16/4885MMP13 17/4885MMP1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.